Last reviewed · How we verify

Adrenaline auto-injector

ALK Nordic A/S, Danmark Filial · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Adrenaline auto-injector is a Small molecule drug developed by ALK Nordic A/S, Danmark Filial. It is currently FDA-approved. Also known as: Jext, Epipen.

An adrenaline auto-injector is a medical device that delivers epinephrine, a small molecule, to treat conditions such as anaphylaxis. It is used to administer epinephrine injection, which is a treatment for anaphylaxis, a severe and potentially life-threatening allergic reaction.

At a glance

Generic nameAdrenaline auto-injector
Also known asJext, Epipen
SponsorALK Nordic A/S, Danmark Filial
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Adrenaline auto-injector

What is Adrenaline auto-injector?

Adrenaline auto-injector is a Small molecule drug developed by ALK Nordic A/S, Danmark Filial.

Who makes Adrenaline auto-injector?

Adrenaline auto-injector is developed and marketed by ALK Nordic A/S, Danmark Filial (see full ALK Nordic A/S, Danmark Filial pipeline at /company/alk-nordic-a-s-danmark-filial).

Is Adrenaline auto-injector also known as anything else?

Adrenaline auto-injector is also known as Jext, Epipen.

What development phase is Adrenaline auto-injector in?

Adrenaline auto-injector is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing